Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903/AMC-080 trial

We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV in a phase 2 prospective multicenter trial. The primary endpoint was 100-day non-relapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least a 7/8 HLA-matched unrelated don...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Biol Blood Marrow Transplant
Auteurs principaux: Ambinder, Richard F., Wu, Juan, Logan, Brent, Durand, Christine M., Shields, Ryan, Popat, Uday R., Little, Richard F., McMahon, Deborah K., Cyktor, Joshua, Mellors, John W., Ayala, Ernesto, Kaplan, Lawrence D., Noy, Ariela, Jones, Richard J., Howard, Alan, Forman, Stephen J., Porter, David, Arce-Lara, Carlos, Shaughnessy, Paul, Sproat, Lisa, Hashmi, Shahrukh K., Mendizabal, Adam M., Horowitz, Mary M., Navarro, Willis H., Alvarnas, Joseph C.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6907401/
https://ncbi.nlm.nih.gov/pubmed/31279752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.06.033
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires